ShadowBuys
Sign inJoin for free

Regeneron Pharmaceuticals (REGN)

Healthcare · Biotechnology

14 members of Congress have disclosed 47 trades in Regeneron Pharmaceuticals (REGN) since 2014: 20 buys and 27 sales. The most recent was disclosed on Oct 7, 2026. 1 trade was made by members of a committee that oversees Regeneron Pharmaceuticals's industry.

Trades disclosed
47
Members trading
14
Buys / sells
20 / 27
Reported value
$103K–$845K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow REGN

What else is happening at REGN

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. REGNFinancial report·SEC EDGAR

    REGN: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 30, 2026, 6:55 AM EDTEvent / period: Sep 30, 2026Original source ↗
  2. REGNCompany announcement·SEC EDGAR

    REGN: Financial results

    Filed 8-K for an event or period dated 2026-10-30. Financial results.

    Public: Oct 30, 2026, 6:50 AM EDTEvent / period: Oct 30, 2026Original source ↗
  3. REGNCompany announcement·SEC EDGAR

    REGN: Material agreement · Financial results · Other company developments

    Filed 8-K for an event or period dated 2026-10-01. Material agreement; Financial results; Other company developments.

    Public: Oct 6, 2026, 7:51 AM EDTEvent / period: Oct 1, 2026Original source ↗
  4. REGNRegulatory notice·Federal Register

    Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal

    The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.

    Public: Oct 1, 2026Original source ↗
  5. REGNCompany announcement·SEC EDGAR

    REGN: Leadership change

    Filed 8-K for an event or period dated 2026-09-24. Leadership change.

    Public: Sep 30, 2026, 4:14 PM EDTEvent / period: Sep 24, 2026Original source ↗

Committee overlaps

Trades by members of a committee that oversees Regeneron Pharmaceuticals's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded REGN

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.